🔬Cell & Gene Therapy
Living cell-based treatments including CAR-T, stem cells, and engineered immune cells for cancer and genetic diseases.
Market Cap$1.4T
1D-1.40%
Companies772
Public Cos59
SECTOR MARKET CAP
$1.4T+4545.8%ALL
TOP COMPANIES
| # | Company | Country | Valuation | Ticker |
|---|---|---|---|---|
| 1 |  | United States | $566.9B | JNJ |
| 2 |  | Switzerland | $278.6B | NVS |
| 3 |  | United States | $170.3B | GILD |
| 4 |  | United States | $117.1B | BMY |
| 5 |  | United Kingdom | $103.7B | GSK |
| 6 |  | Japan | $56.3B | TAK |
| 7 |  | Switzerland | $41.6B | LONN.SW |
| 8 |  | China | $17.2B | WXXWY |
| 9 |  | United States | $10.4B | BMRN |
| 10 |  | United States | $8.7B | IBRX |
| 11 |  | United States | $7.4B | KRYS |
| 12 |  | United States | $6.7B | ACLX |
| 13 |  | United States | $1.8B | SRPT |
| 14 |  | United States | $1.7B | CAPR |
| 15 |  | United States | $1.6B | VCEL |
| 16 |  | United States | $1.5B | IOVA |
| 17 |  | Germany | $1.3B | IMTX |
| 18 |  | United States | $1.2B | TSHA |
| 19 |  | United States | $1.2B | PGEN |
| 20 |  | Denmark | $1.1B | CHEMM.CO |